Scholar Rock Holding Corp - 8-K Filing
Scholar Rock to sell FDA Priority Review Voucher to BioNTech for $205 million and reports Q3 2026 ISEMBYLD revenue of $0.6 million. (Items: 1.01 Entry into a Material Definitive Agreement, 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $SRRK
Read the full article at SEC EDGAR
Part of the story Imunon, Inc. - 8-K Filing (38 articles)